Resistance development profiling of piperacillin in combination with the novel -lactamase inhibitor BLI-489
Authors:
Open Access
- 11 December 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 65 (2) , 252-257
Abstract
To evaluate development of resistance to the piperacillin/BLI-489 combination. BLI-489 was used at a constant concentration of 4 mg/L. Spontaneous mutation frequency was measured on piperacillin/BLI-489-containing agar plates. Five β-lactamase-producing strains were exposed to a serial dilution of piperacillin/BLI-489, and the highest concentration allowing growth was used to inoculate subsequent serial passage for 10 days. Mutation stability was monitored in drug-free medium for 10 days. Escherichia coli (OXA-3, OXA-7, ACT-1, SHV-1 or none), Salmonella enterica serovar Typhimurium (CTX-M-5), Klebsiella pneumoniae (SHV-1 and SHV-5) and Enterobacter cloacae (AmpC) had a spontaneous mutation frequency of ≤1.0 × 10−9. Two AmpC-producing Pseudomonas aeruginosa strains had a mutation frequency of 6.52 × 10−6 and 1.0 × 10−7; a β-lactamase-negative P. aeruginosa strain had a mutation frequency of 2.68 × 10−8. The mutant prevention concentration (MPC) was ≤32 mg/L. During serial passages, the MIC increased 64- and 128-fold for S. enterica serovar Typhimurium (CTX-M-5) and E. cloacae (AmpC), respectively, to ≥512 mg/L. The MIC reverted to ≤64 mg/L after serial passages in drug-free medium. The MICs increased only 4-fold for K. pneumoniae (SHV-1 and SHV-5), E. coli (OXA-3) and E. coli (SHV-1). Piperacillin/BLI-489 demonstrated a low probability of spontaneous resistance development in vitro for all of the strains tested with the exception of P. aeruginosa. The MPC value for all strains was ≤32 mg/L. Resistance developed during serial passage for two of the five strains tested; however, this resistance phenotype was unstable as MIC values reverted to ≤64 mg/L after propagation in drug-free medium.Keywords
This publication has 11 references indexed in Scilit:
- Efficacy of Piperacillin Combined with the Penem β-Lactamase Inhibitor BLI-489 in Murine Models of Systemic InfectionAntimicrobial Agents and Chemotherapy, 2009
- Establishment of In Vitro Susceptibility Testing Methodologies and Comparative Activities of Piperacillin in Combination with the Penem β-Lactamase Inhibitor BLI-489Antimicrobial Agents and Chemotherapy, 2009
- Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2009
- Failure of Cefepime Therapy in Treatment of Klebsiella pneumoniae BacteremiaJournal of Clinical Microbiology, 2005
- A Novel MATE Family Efflux Pump Contributes to the Reduced Susceptibility of Laboratory-Derived Staphylococcus aureus Mutants to TigecyclineAntimicrobial Agents and Chemotherapy, 2005
- Selection during Cefepime Treatment of a New Cephalosporinase Variant with Extended-Spectrum Resistance to Cefepime in an Enterobacter aerogenes Clinical IsolateAntimicrobial Agents and Chemotherapy, 2004
- Plasmid-borne AmpC β-lactamasesCanadian Journal of Microbiology, 2002
- Plasmid-Determined AmpC-Type β-LactamasesAntimicrobial Agents and Chemotherapy, 2002
- Evolution and epidemiology of extended-spectrum β-lactamases (ESBLs) and ESBL-producing microorganismsClinical Microbiology and Infection, 2001
- β-Lactamase Inhibitors: Agents to Overcome Bacterial ResistanceCurrent Medicinal Chemistry, 1998